Sequence Specific Inhibition of Protein Translation

蛋白质翻译的序列特异性抑制

• 批准号: 10196539
• 负责人: John S Chorba
• 金额: $ 24.23万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-04-01 至 2023-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10196539
• 关键词: Active Sites; Address; Affect; Amino Acid Sequence; Amino Acids; Antibiotics; Atherosclerosis; Binding; Biological; Biomedical Research; Cell physiology; Cells; Chemicals; Clinic; Clinical; Code; Codon Nucleotides; Communities; Cysteine; Development; Disease; Economics; Emerging Technologies; Failure; Gene Silencing; Goals; Gold; Human; Kinetics; Knowledge; Mediating; Methods; Molecular; Molecular Evolution; Oral; Peptides; Peptidyltransferase; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmacology; Process; Production; Protein Inhibition; Proteins; Research; Ribosomes; Specificity; Structure; System; Technology; Testing; Therapeutic; Therapeutic Studies; Thermodynamics; Translating; Translations; analog; base; biochemical tools; chemical genetics; cost; drug discovery; improved; inhibitor/antagonist; innovation; interest; novel; personalized strategies; prevent; protein aminoacid sequence; small molecule; theories; therapeutic target; tool; translatome

PROJECT SUMMARY/ABSTRACT An inherent challenge in drug discovery is that every target requires its own individualized strategy. Many targets are “undruggable” by small molecules, which, owing to their rapid onset and low cost, are the pharmacologic cornerstone of both clinical therapies and research tools alike. A generalizable solution to inhibit the function of any given protein with a small molecule is therefore a holy grail of biomedical research. A possible solution exists in a recently described small molecule which stalls the translation of a very limited number of protein targets. This class of molecules binds in the ribosome exit tunnel to allosterically alter the peptidyl transferase center and prevent elongation, doing so in a manner that is dependent on the sequence identity of nascent chain. Though this novel mechanism of action is exciting, the off-target effects of the current compounds precludes their use either as therapeutics or as a clean sequence-specific chemical probe. In this proposal, we will directly address whether these compounds can be developed into useful research tools. In Aim 1, we will probe the intrinsic limits of the specificity of this technology, doing so by developing an optimized chemical genetics pair between the known compounds and an evolved target peptide sequence. In Aim 2, we will evaluate whether the maximum efficacy of these compounds can be improved by developing covalent analogs that can target specific cysteine-containing nascent chains. In Aim 3, we will ask whether the structures of the compounds can be tuned to alter the sequence specificity of the nascent chains they target. We will do this via an innovative kinetic target-templated synthetic strategy, which will simultaneously probe the accessible chemical space of the binding pocket with the exit tunnel, while also producing nascent chain specific chemical probes. We anticipate that advances in any one of these Aims would allow this technology to be further developed into a powerful tool: the ability to stop, and then restart, the protein production of any target of interest.

项目总结/摘要 药物发现的一个固有挑战是，每个目标都需要自己的个性化策略。许多 小分子的靶点是“不可抵抗的”，由于它们起效快，成本低， 药理学是临床治疗和研究工具的基石。一种普遍适用的解决方案， 因此，具有小分子的任何给定蛋白质的功能是生物医学研究的圣杯。一 可能的解决方案存在于最近描述的小分子中，该小分子使非常有限的 蛋白质目标的数量。这类分子结合在核糖体出口通道中，以变构地改变核糖体的结构。 肽基转移酶中心和防止延伸，这样做的方式是依赖于序列 新生链的身份。尽管这种新的作用机制令人兴奋，但电流的脱靶效应 化合物排除了它们作为治疗剂或作为干净的序列特异性化学探针的用途。在这 我们将直接讨论这些化合物是否可以发展成为有用的研究工具。在 目标1，我们将探索这种技术的特异性的内在限制，通过开发一种优化的 已知化合物和进化的靶肽序列之间的化学遗传学配对。在目标2中， 将评估是否可以通过开发共价键来提高这些化合物的最大功效。 可以靶向特定的含半胱氨酸的新生链的类似物。在目标3中，我们会问， 可以调整化合物的结构以改变它们所靶向的新生链的序列特异性。 我们将通过一种创新的动力学靶模板合成策略来实现这一目标，该策略将同时探测 可访问的化学空间的结合口袋与出口隧道，同时也产生新生链 特定的化学探针我们预计，这些目标中任何一个的进步都将使这项技术能够 进一步发展成为一个强大的工具：能够停止，然后重新启动，任何蛋白质的生产 感兴趣的目标。